Leung, Clarus and Gilchrist, Cassie L and Wang, Carolyn J and Liggins, James A and Li, Xuan and Yang, Julia and Cheung, Chung Y and Gerayeli, Firoozeh V and Singhera, Gurpreet K and Hsu, Wu Jih and Lidher, Lavraj S and Moo, Karolina and Leyson, Eleazar and Dhillon, Satvir S and Shaipanich, Tawimas and Leipsic, Jonathon A and Guenette, Jordan A and Rayment, Jonathan H and Kirby, Miranda and Gershon, Andrea S and Sadatsafavi, Mohsen and Tan, Wan C and Parraga, Grace and Carlsten, Christopher and Eddy, Rachel L and Sin, Don D and Leung, Janice M (2026) Clinical, physiological, imaging and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) study. European Respiratory Journal, 67, (1), 2501659. DOI: https://doi.org/10.1183/13993003.01659-2025.
External website: https://publications.ersnet.org/content/erj/67/1/2...
BACKGROUND: The growing popularity of cannabis smoking in an era of legalisation has prompted concerns about respiratory health.
OBJECTIVE: To investigate clinical and airway epithelial transcriptomic features associated with cannabis smoking.
METHODS: This cross-sectional study analysed data from 139 cannabis-smoking participants categorised by joint-year exposure (low: ≤5; moderate: >5-20; high: >20 joint-years) and 57 never-smokers. We evaluated respiratory symptom questionnaire scores, lung function measurements, chest computed tomography and hyperpolarised Xenon pulmonary magnetic resonance imaging measurements across groups. We compared the expression of immune response signatures and mucin genes in airway epithelial brushings collected from bronchoscopy. Using air-liquid interface cell cultures, we quantified epithelial mucin 5AC (MUC5AC) protein and correlated its expression with clinical outcomes.
RESULTS: Among cannabis-smoking participants (48% male, median age of 27 years), 84% reported current or former cigarette smoking or vaping. Cannabis-smoking groups reported worse respiratory symptoms than never-smokers. High joint-year cannabis-smoking participants showed lower pre-bronchodilator forced expiratory volume in 1 s to forced vital capacity ratio, lower forced expiratory flow at 25-75% of the forced vital capacity, more radiographic emphysema and more ventilation abnormalities than never-smokers. Airway epithelial brushings from cannabis-smoking participants demonstrated an increased type 2 immune response, decreased type 17 immune response and higher gene expression than non-cannabis-smoking participants. Epithelial MUC5AC protein expression in cell cultures correlated with worse clinical outcomes and imaging abnormalities.
CONCLUSIONS: Cannabis smoking, particularly at high exposures, is associated with worse respiratory symptoms, lower lung function, functional imaging abnormalities and dysregulated immune responses in the airway epithelium. These observations suggest respiratory harm associated with cannabis smoking and underscore the concerns for future respiratory morbidities related to persistent cannabis use.
B Substances > Cannabis / Marijuana
E Concepts in biomedical areas > Route of administration > Smoke, vape, inhalation
G Health and disease > State of health > Physical health
G Health and disease > Respiratory / lung disease
VA Geographic area > Canada
Repository Staff Only: item control page